On April 3, 2025, BioXcel Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity to sell up to $8,135,000 of its common stock through an at-the-market offering. Canaccord will receive a commission of up to 3.0% on the sales made under this agreement.